Biohit Oyj
OMXH:BIOBV
Gross Margin
Biohit Oyj
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| FI |
B
|
Biohit Oyj
OMXH:BIOBV
|
41m EUR |
65%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
224.3B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
183.1B USD |
67%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
150.7B USD |
69%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
139.8B USD |
64%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.8B USD |
66%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.9B EUR |
38%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.3B USD |
45%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.5B USD |
79%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
264.6B CNY |
64%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
35.4B USD |
61%
|
Biohit Oyj
Glance View
Biohit Oyj engages in the development, manufacture, and market of diagnostic tests and analysis systems. The company is headquartered in Helsinki, Etela-Suomen. The firm operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. The company provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Company’s products are used in hospitals, healthcare centers and research institutions. The company operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Biohit Oyj's most recent financial statements, the company has Gross Margin of 65.4%.
You don't have any saved screeners yet